Department of Pediatrics, Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, Québec, Canada; Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Québec, Canada.
McGill Adult Unit for Congenital Heart Disease Excellence, McGill University Health Centre, Montréal, Québec, Canada.
Can J Cardiol. 2021 Jun;37(6):877-886. doi: 10.1016/j.cjca.2020.10.002. Epub 2020 Oct 12.
The reported survival of tetralogy of Fallot (TOF) is > 97%. Patients with pulmonary atresia and/or genetic conditions have worse outcomes, but long-term estimates of survival and morbidity for these TOF subgroups are scarce. The objective of this study was to describe the 30-year outcomes of TOF according to native anatomy and the coexistence of genetic conditions.
The TRIVIA (Tetralogy of Fallot Research for Improvement of Valve Replacement Intervention: A Bridge Across the Knowledge Gap) study is a retrospective population-based cohort including all TOF subjects born from 1980 to 2015 in Québec. We evaluated all-cause mortality by means of Cox proportional hazards regression, and cumulative mean number of cardiovascular interventions and unplanned hospitalisations with the use of marginal means/rates models. We computed 30-year estimates of outcomes according to TOF types, ie, classic TOF (cTOF) and TOF with pulmonary atresia (TOF-PA), and the presence of genetic conditions.
We included 960 subjects. The median follow-up was 17 years (interquartile range, 8-27). Nonsyndromic cTOF subjects had a 30-year survival of 95% and had undergone a mean of 2.8 interventions and 0.5 hospitalisations per subject. In comparison, TOF-PA subjects had a lower 30-year survival of 78% and underwent a mean of 8.1 interventions, with 4 times as many hospitalisations. The presence of a genetic condition was associated with lower survival (< 85% for cTOF and < 60% for TOF-PA) but similar numbers of interventions and hospitalisations.
The anatomic types and the presence of genetic conditions strongly influence the long-term outcomes of TOF. We provided robust 30-year estimates for key markers of prognosis that may be used to improve risk stratification and provide more informed counselling to families.
法洛四联症(TOF)的报告生存率>97%。患有肺动脉闭锁和/或遗传疾病的患者预后较差,但这些 TOF 亚组的长期生存和发病率估计数据很少。本研究的目的是根据原发性解剖结构和遗传状况的共存情况,描述 TOF 的 30 年结果。
TRIVIA(法洛四联症研究改善瓣膜置换干预:填补知识空白的桥梁)研究是一项回顾性基于人群的队列研究,包括 1980 年至 2015 年期间在魁北克出生的所有 TOF 患者。我们使用 Cox 比例风险回归评估全因死亡率,并使用边缘均值/率模型评估心血管介入和非计划性住院的累积平均次数。我们根据 TOF 类型(即经典 TOF[cTOF]和 TOF 伴肺动脉闭锁[TOF-PA])以及遗传状况计算 30 年的结果估计。
我们纳入了 960 名患者。中位随访时间为 17 年(四分位距 8-27)。非综合征型 cTOF 患者的 30 年生存率为 95%,平均每位患者接受了 2.8 次干预和 0.5 次住院治疗。相比之下,TOF-PA 患者的 30 年生存率较低,为 78%,平均接受 8.1 次干预,住院次数是前者的 4 倍。遗传状况的存在与较低的生存率相关(cTOF <85%,TOF-PA <60%),但介入和住院次数相似。
解剖类型和遗传状况强烈影响 TOF 的长期结果。我们提供了关键预后标志物的稳健 30 年估计值,可用于改善风险分层并为患者家属提供更明智的咨询。